Seer Inc (NAS:SEER)
$ 1.645 -0.02 (-1.2%) Market Cap: 106.82 Mil Enterprise Value: -172.42 Mil PE Ratio: 0 PB Ratio: 0.28 GF Score: 50/100

Seer Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 11:00PM GMT
Release Date Price: $5.67 (+12.50%)
Ruizhi Qin
JPMorgan Chase & Co, Research Division - Analyst

All right. Good afternoon, ladies and gentlemen. Please take a seat. We're about to get started. I'm Julia Qin, Lead Analyst covering life science tools and diagnostics at JPMorgan, and it's my great pleasure to introduce you to our next company presentation by Seer.

So with that, let me turn it over to Omid. Thank you.

Omid C. Farokhzad
Seer, Inc. - Founder, President, CEO & Chair of the Board of Directors

Hello, everyone. Julia, thanks so much and to the JPMorgan team for invitation to be here. I'm Omid Farokhzad, CEO of Seer company. I founded in 2017 -- December of '17 and took public in December of '20. In January of '21, we brought in our flagship product, the Proteograph Product Suite in limited release to customers. And a year ago, this time, we brought the product into a broad commercial release. So today, I'm going to take you through some of the progress we've made over the past year, tell you about some of the commercial traction, what the customers are saying. And then

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot